Navigation Links
Resverlogix Share Option Extension

TSX Exchange Symbol: RVX

CALGARY, April 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that 948,700 stock options due to expire April 25, 2008 will automatically be extended pursuant to the Company's stock option plan and in accordance with TSX Staff Notice 2006-0001. The Company's stock option plan provides that in the event that stock options would otherwise expire during a "blackout" trading restriction imposed by the Company under its Corporate Governance Policy, then such options shall be extended until 10 business days following the date the black out period is lifted by the Company. This is to give the option holders fair and reasonable opportunity to exercise their options.

While it is not the Company's normal policy to publicize blackout dates, given the significant number of options in question and the fact they are held by directors and senior officers of the Company, Resverlogix desired to clarify the options' status to ensure the market was not in any way misled. It is not known at this time when the blackout period will be lifted.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
2. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
3. Resverlogix is Presenting at IAS HDL Workshop
4. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
5. Investors Acquire Share in Sangui BioTech GmbH
6. BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock
7. Chromos provides shareholder update
8. Arpida Announces Agenda Items for Shareholders Meeting
9. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
10. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
11. ARIUS 2008 Annual and Special Meeting of Shareholders
Post Your Comments:
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
Breaking Biology Technology:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
Breaking Biology News(10 mins):